Fennec Pharmaceuticals (FENC) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Tevogen (TVGN) over the past year, gaining 66.1% versus a loss of 73.8%. Fennec Pharmaceuticals is the larger company by market cap ($462.1 million vs $405.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | TVGN |
|---|---|---|
| Share price | $13.09 | $5.90 |
| Market cap | $462.14M | $405.20M |
| 1-day change | -2.68% | -6.35% |
| YTD return | +70.00% | -64.35% |
| 1-year return | +66.12% | -73.84% |
| 5-year return | +35.79% | — |
| P/E ratio (TTM) | 436.33 | — |
| Forward P/E | 12.47 | — |
| EPS (TTM) | $0.03 | $-7.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.64M | — |
| Revenue growth (YoY) | -6.09% | — |
| Net income (latest FY) | $-9.74M | $-26.28M |
| Operating margin | -14.07% | — |
| Net margin | -21.82% | — |
| 52-week high | $13.85 | $24.90 |
| 52-week low | $5.65 | $3.64 |
| Distance from 52-week high | -5.49% | -76.31% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +34.45% | — |
| Average volume | 220.87K | 7.94K |
| Shares outstanding | 35.31M | 68.68M |
| Employees | 35 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed TVGN by 140.0 percentage points over the past year.
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
FENC vs TVGN FAQ
Which is bigger, Fennec Pharmaceuticals or Tevogen?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $462.14M compared with $405.20M for Tevogen (TVGN).
Which stock has performed better over the past year, FENC or TVGN?
FENC returned +66.12% over the past 12 months, compared with -73.84% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.